

Submission Confirmation for Fabrication of a Tailored, Hybrid Extracellular Matrix Composite (mabi.202200106)

1 message

Macromolecular Bioscience <em@editorialmanager.com>
Reply-To: Macromolecular Bioscience <mabi@wiley-vch.de>
To: Agustina Setiawati <nina.lifesci@gmail.com>

Fri, Mar 11, 2022 at 3:51 PM

You are being blind carbon copied ("bcc:'d") on an e-mail "To" "Kwanwoo Shin" kwshin@sogang.ac.kr

Dear Dr. Shin,

Your submission entitled "Fabrication of a Tailored, Hybrid Extracellular Matrix Composite" has been received by journal Macromolecular Bioscience. The manuscript number for your submission is mabi.202200106.

To view your submission, please login to <https://www.editorialmanager.com/mbs-journal/> by entering your username (*****) and password and selecting the "Author Login" option. Please note that the current status of your submission will remain "Under consideration" until an editorial decision is made, at which time you will be notified by e-mail.

If the manuscript is accepted for publication, this author's affiliation will be used to determine eligibility for some open access funding (click [here](#) for details).

This journal offers a number of license options; information about this is available [here](#). The submitting author has confirmed that all co-authors have the necessary rights to grant in the submission, including in light of each co-author's funder's policies. If any author's funder has a policy that restricts which kinds of license they can sign, for example if the funder is a member of Coalition S, please make sure the submitting author is aware.

This message has been sent to all named co-authors listed in the submission process to serve as notification of submission.

Thank you for submitting your work to the journal.

Kind regards,

Editorial Office

Macromolecular Bioscience
E-mail: mabi@wiley-vch.de
Tel: +49(0)6201-606-581

<http://www.mbs-journal.de>

Impact Factor (2021 Journal Citation Reports): 4.979

Please find a copy of the submission questions, which you answered during the submission, for your records:

Additional Information

7. Kwanwoo Shin, Ph.D.

Question	Response
Please submit a plain text version of your cover letter here.	Dear Editor of Macromolecular Bioscience Editorial We would like to submit a new manuscript entitled "Fabrication of a Tailored, Hybrid Extracellular Matrix Composite" for publication as a communication in Macromolecular Bioscience Editorial. We engineered a hybrid ECM scaffold fabricated by externally depositing a desired the ECM components to native ECM from fibroblast as a structural template on fibronectin micropattern. This manuscript describes how single external ECM component are integrated to the native fibrous ECM structure. Thus, the deposition of multi component ECM also remarkably formed hybrid scaffolds (Figure 2 & Movie S1-4) with

a variety of ECM compositions. These findings open the opportunity of possibility of realizing a desired ECM composition in a native ECM network.

We envision that this approach to control the composition of ECM components by manipulating the concentration of externally added ECM components, to fabricate tailored ECMs. Here, we successfully transformed skin-derived ECM into either a liver tissue resembling FN-rich ECM or a breast tissue resembling COL I-rich ECM. It answered an important challenge to tailor ECM component scaffold through a simple and facile method. To test, the functionality of our FN-rich ECM support hepatocyte cells' life and significantly different from the controls. We believe that our approach is promising for the production of scaffolds that provide a tailored cellular microenvironment to specific organs and ultimately serve as a novel pathway for tissue engineering that can replace or regenerate specific organ tissues.

We believe that the subject matter and quality of this work ideally suit it for publication in Macromolecular Bioscience Editorial, and that, given the interdisciplinary nature of the project, the paper will be of interest to a broad audience. We thank you in advance for your time and consideration on our behalf.

Sincerely,

Kwanwoo Shin, Professor and Director
Department of Chemistry and Institute of Biological Interfaces
Sogang University, 35 Baekbeom-ro, Mapo, Seoul 04107, Korea

Please confirm that the research and manuscript meet the ethical guidelines outlined in this journal's [Author Guidelines](#), including adherence to the legal requirements of the study country.

Yes, I confirm

Does the research described in this manuscript include animal experiments?

No

Does the research described in this manuscript include human research participants (including for experiments with sensors or wearable technologies) or tissue samples from human subjects (including blood or sweat)?

No

Do you or any of your co-authors have a conflict of interest to declare?

No. The authors declare no conflict of interest.

Please review this journal's licensing options. The submitting author is expected to consult all authors to find out whether any of their funders has a policy that restricts which kinds of licenses they can sign, for example, if the funder is a member of Coalition S.

Yes, all co-authors have reviewed this journal's licensing options and, on behalf of all co-authors, I confirm that all co-authors have the full power, authority, and capability (i) to agree to the terms of one of the licenses offered by this journal and (ii) to grant the rights set forth in such license for the publication of this submission.

Information about licensing options is available [here](#).

This journal supports data sharing and has adopted an [Expects Data Sharing](#) policy:

- You are encouraged to make your data available, for instance in a public repository.
- Your article must include a Data Availability Statement; please select a template from the options below or provide a custom Statement.
- When data is openly available, please provide the name and URL/DOI of the repository and cite the data in the references section of your manuscript.

Data available in article supplementary material

Is your data available?

Please confirm the selected template for your Data Availability Statement below, which will be published as part of your article if it is accepted for publication.

as follow-up to "This journal supports data sharing and has adopted an [Expects Data Sharing](#) policy:

The data that support the findings of this study are available in the supplementary material of this article.

- You are encouraged to make your data available, for instance in a public repository.

- Your article must include a Data Availability Statement; please select a template from the options below or provide a custom Statement.

- When data is openly available, please provide the name and URL/DOI of the repository and cite the data in the references section of your manuscript.

Is your data available?"

Macromolecular Bioscience publishes Accepted Articles (i.e. "Accepted Versions") on Wiley Online Library prior to publication of the final Version of Record. To facilitate rapid dissemination of your work, the Accepted Version of your article can be published online before copyediting, typesetting, and proofreading.

The Accepted Version will be published under Terms and Conditions given [here](#).

Please give details of any related submission that has previously been considered by this journal.

Please give details of any related work that is currently being considered, or will be considered in the near future, by this editorial office or any other publisher.

Please indicate if your work has been funded by any of the following funding bodies:

Yes, I give Wiley permission to publish the Accepted Version of my manuscript if accepted and I have read and agree to the [Terms and Conditions](https://authorservices.wiley.com/statements/accepted-version-terms-and-conditions.html?1) for its publication, including that my manuscript is original and does not infringe others' rights.

Join us in our virtual symposium "Spotlights in Advanced Science" co-organized by our journals *Advanced Science* and *Small Science*.

More details and registration on Session 1: Advances in Biomedical Research available at

<https://register.gotowebinar.com/register/1094407016075880460?source=editor>

and on Session 2: Advances in Smart Materials and Energy Research at

<https://register.gotowebinar.com/register/4715535312671857423?source=Editor+Share>.

MRC Special Issue: 100 Years of Macromolecular Chemistry (Free Access)

<http://doi.wiley.com/10.1002/marc.v41.1>

MCP Special Issue: 100 Years of Macromolecular Chemistry (Free Access)

<http://doi.wiley.com/10.1002/macp.v221.1>

MBS Special Issue: 20 Years of Macromolecular Bioscience (Free Access)

<http://doi.wiley.com/10.1002/mabi.v20.1>

We invite you to celebrate 100 years of polymer science with us. Check out for details at: www.chemistryviews.org/polymer100

By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services, and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at <https://authorservices.wiley.com/statements/data-protection-policy.html>

Wiley-VCH GmbH - A company of John Wiley & Sons, Inc. - Location of the Company: Weinheim - Trade Register Mannheim, HRB 736569. Chairman of the Supervisory Board: John Kritzmacher. Managing Directors: Sabine Haag, Dr. Guido F. Herrmann.

Please be aware that if you ask to have your user record removed, we will retain your name in the records concerning manuscripts for which you were an author, reviewer, or editor.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. ([Remove my information/details](#)). Please contact the publication office if you have any questions.

**FW: Revision request for your submission to Macromolecular Bioscience
(mabi.202200106)**

1 message

kwshin@sogang.ac.kr <kwshin@sogang.ac.kr>
Reply-To: kwshin@sogang.ac.kr
To: Agustina Setiawati <nina.lifesci@gmail.com>
Cc: Ivan Brilian <ivan@sogang.ac.kr>

Mon, May 2, 2022 at 8:58 AM

Nina,

We received the revision, hopefully we can complete it and move on.

Since we do not have much time for your graduation, I need to take a look at the revision request, as CAREFULLY and THOROUGHLY as possible, and send me back ASAP.

Ivan, I want you to work with Nina and input your thought and strategy. Revision letter is Ph.D's last mission, and wish it goes smoothly.

KS.

-----Original Message-----

From: em.mbs-journal.0.7afa11.401c3c8e@editorialmanager.com <em.mbs-journal.0.7afa11.401c3c8e@editorialmanager.com>
On Behalf Of Macromolecular Bioscience
Sent: Friday, April 29, 2022 5:59 PM
To: Kwanwoo Shin <kwshin@sogang.ac.kr>
Subject: Revision request for your submission to Macromolecular Bioscience (mabi.202200106)

Dear Prof. Shin,

Thank you for submitting your manuscript entitled "Fabrication of a Tailored, Hybrid Extracellular Matrix Composite" (Research Article, No. mabi.202200106) to Macromolecular Bioscience. The reviewer report and comments are included at the end of this e-mail.

I am pleased to inform you that your manuscript has been recommended for publication pending satisfactory revisions. I invite you to respond to the reviewer comments and make the necessary changes to your manuscript.

To submit your revision, go to <https://www.editorialmanager.com/mbs-journal/> and log in as an Author using your username (kwshin) and password. Your submission can be found under the menu item "Submissions Needing Revision". The changes to your manuscript should be highlighted in a different color in the primary "Revised Manuscript" file.

Please provide a point-by-point response letter addressed to the reviewers, including a list of changes made and a rebuttal to any comments with which you disagree. You may copy the letter into the "Respond to Reviewers" box (if it is plain text only) or upload it as a "Response Letter to Reviewers" item (if it contains figures, tables, or special formatting such as formulas or equations). If necessary, you may also upload a separate revision cover letter addressed to the editor with any other information not intended for reviewers as a "Cover Letter to Editor" item. You will also be asked to upload a .zip archive containing the production data that will be used if your manuscript is accepted. See below for more details.

We should receive your revised manuscript by 29 May 2022. Once we receive your revised manuscript, we will provide a final decision as soon as possible.

We recognize that authors are doing their best to revise manuscripts under challenging circumstances due to the COVID-19 pandemic. Should you need extra time, do not hesitate to contact the editorial office.

Yours sincerely,

Anne Pfisterer

P.S. Please help avoid delays by referring to the Manuscript Preparation Checklist (<http://www.mbs-journal.com/authorguidelines>) and use the appropriate article template when preparing your revised manuscript. Please also follow the instructions to prepare and upload your Production Data materials. These include: the full, non-highlighted text of your manuscript (with all figures with a resolution of at least 300 dpi, schemes, and tables) in editable format - Word DOC/X or LaTeX; a short summary (50-60 words) and an eye-catching color image for the Journal's Table of Contents; and, if applicable, Supporting Information*.

*The Supporting Information document(s) will be published alongside your article and should be non-highlighted and ready for

publication. Video formats may also be included.

P.S.: To find out whether the cost of publishing your manuscript Open Access is covered by one of our national agreements, check our website: <https://authorservices.wiley.com/author-resources/Journal-Authors/open-access/affiliation-policies-payments/index.html>. The primary corresponding author's affiliation is to be used to determine eligibility for some open access funding. It is important to correctly select this affiliation to qualify for these funds.

REVIEWER REPORT:

Please note that reviewers may not be numbered consecutively. Where reviewers have provided additional files, these are available here:

EVALUATION:

Reviewer's Responses to Questions

Please rate the importance compared to published work in this subject area.

Reviewer #1: Moderate - Top 50% in the subject area

Reviewer #3: Considerable - Top 30% in the subject area

Please rate the novelty compared to published work in this subject area.

Reviewer #1: Moderate - Top 50% in the subject area

Reviewer #3: Considerable - Top 30% in the subject area

Which aspects of scholarly presentation require improvement (if any)?

Reviewer #1: (No Response)

Reviewer #3: (No Response)

Do the methods, data and analysis (including statistical analysis where applicable) adequately test the hypothesis and support the conclusions?

Reviewer #1: (No Response)

Reviewer #3: Yes

Are the methods, data and analysis described in sufficient detail to be reproduced?

Reviewer #1: None

Reviewer #3: Yes

What do you anticipate your overall rating (a mean of importance, novelty and scholarly presentation) would be if the requested revisions are adequately addressed?

Reviewer #1: (No Response)

Reviewer #3: High - Top 15% in the subject area

COMMENTS TO AUTHOR:

Reviewer #1: The work by Setiawati et al group revolves around the fabrication of a hybrid ECM scaffold that can combine the properties of native ECM and artificial scaffold. Given the complexity in developing a scaffold that closely resembles to the natural

ECM, the authors tailored a native ECM scaffold by culturing fibroblasts on Fibronectin micropattern to promote ECM formation. Addition of FN and COL1A externally to the cellularized ECM scaffold promoted the formation of complex hybrid fibers which is interesting. Further, they added FN, Col1a and LN separately to the native ECM and demonstrated different patterning caused by different ECM components. They also demonstrated that the native ECM changes with increasing composition of COL1A and FN that can be applicable in different tissue scenarios. However, there are questions:

1. No SEM images are shown to understand the difference in the FNp, cFN and Hybrid ECM. Addition of different ECM materials promotes specific patterning of the hybrid scaffold which is shown in confocal images but SEM images are missing.
2. Efficiency of decellularization such as evaluation of DNA content is missing.
3. Recellularization with hepatoma cell line is misleading as these cells are tumorigenic. Normal hepatic cell lines such as HL 7702 should be used.
4. In Figure 1, it was mentioned that Col1a rich hybrid ECM scaffold can be used for breast mimicking ECM. No test was conducted to prove that cells of breast origin can recellularize on the Col1a rich hybrid ECM scaffold.

Reviewer #3: The authors present a clever process where they design and build a hybrid ECM scaffold from fibronectin and collagen (COL I) templated on native ECM structures derived from living cells. The approach is simple yet unique and demonstrates a fresh way to think about engineering new tissue mimetics specific to different cell types. While the work is fantastic and should be published here, the introduction and motivation is lacking. In general, a discussion of the current state of the art in tissue mimetics and how these materials compare is missing throughout. Specific comments:

- The cons associated with decellularized then recellularized scaffolds are not clear. The authors state on pg 2 lines 63-65 "However, due to the composition and the architectural complexity of native ECM, the use of a single or a few components in the fabrication of tissue scaffolds cannot fully recapitulate its properties, restricting the production...of a universally applicable scaffold" Why is there a need for a universal scaffold, when every region of the body has a protein composition that is unique to their cell type/function? Please clarify. Also, the authors are not creating a universal scaffold either. So, it is unclear how their approach advances what has been done in the past.
- In the same regard, the text on artificial scaffolds is limited, lacking any citations and the argument for why there is a need of new materials here is lacking. The authors should include a more in depth discussion of the current state of the art in ECM mimetics, as much has been done to address this.
- What is the native "structure of natural ECM systems" (line 76-77 pg 3) that the authors wish to standardize? They should be more explicit on the exact chemical features and relative compositions they would like to emulate. What constitutes a "desired composition" (pg 4 line 96)? Without this information, it is difficult to assess if the authors are successful. In this regard, the paper would benefit from a supplemental table that highlights the relative compositions of each of the tissues they aim to mimic. Are the relative protein abundances represented in Figure 1a based on data? If so, it would be great to see those numbers with citations.
- I am curious how cells cultured on a non decell/recellularized protein enriched substrates would look like in each condition? Did the authors do this control to account for confluency of cells in the a scaffold that was simply decellularized and reseeded with the tissue specific cells? How did cell density counts vary compared to the enriched scaffolds (this would be separate from the FN control)?

--
Dr. Anne Pfisterer, Editor
Macromolecular Bioscience
E-mail: mabi@wiley-vch.de
Tel: +49(0)6201-606-581

<http://www.mbs-journal.de>

Impact Factor (2021 Journal Citation Reports): 4.979

MRC Special Issue: 100 Years of Macromolecular Chemistry (Free Access)

<http://doi.wiley.com/10.1002/marc.v41.1>

MCP Special Issue: 100 Years of Macromolecular Chemistry (Free Access)

<http://doi.wiley.com/10.1002/macp.v221.1>

MBS Special Issue: 20 Years of Macromolecular Bioscience (Free Access)

<http://doi.wiley.com/10.1002/mabi.v20.1>

We invite you to celebrate 100 years of polymer science with us. Check out for details at: www.chemistryviews.org/polymer100

By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services, and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at <https://authorservices.wiley.com/statements/data-protection-policy.html>

Wiley-VCH GmbH - A company of John Wiley & Sons, Inc. - Location of the Company: Weinheim - Trade Register Mannheim, HRB 736569. Chairman of the Supervisory Board: John Kritzmacher. Managing Directors: Sabine Haag, Dr. Guido F. Herrmann.

Please be aware that if you ask to have your user record removed, we will retain your name in the records concerning manuscripts for which you were an author, reviewer, or editor.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/mbs-journal/login.asp?a=r>). Please contact the publication office if you have any questions.

FW: Acceptance of your submission to Macromolecular Bioscience (mabi.202200106R1) - [EMID:d8256e865f85986b]

2 messages

kwshin@sogang.ac.kr <kwshin@sogang.ac.kr>
Reply-To: kwshin@sogang.ac.kr
To: Agustina Setiawati <nina.lifesci@gmail.com>
Cc: Ivan Brilian <ivan@sogang.ac.kr>

Wed, Jun 8, 2022 at 4:48 PM

Nina, your paper has been accepted. Ask Prof.Jung whether there is way to proceed your degree.

-----Original Message-----

From: em.mbs-journal.0.7bda68.01ab5b91@editorialmanager.com <em.mbs-journal.0.7bda68.01ab5b91@editorialmanager.com>
On Behalf Of Macromolecular Bioscience
Sent: Wednesday, June 8, 2022 3:10 PM
To: Kwanwoo Shin <kwshin@sogang.ac.kr>
Subject: Acceptance of your submission to Macromolecular Bioscience (mabi.202200106R1) - [EMID:d8256e865f85986b]

Dear Prof. Shin,

Thank you for submitting your manuscript entitled "Fabrication of a Tailored, Hybrid Extracellular Matrix Composite" (Research Article, No. mabi.202200106R1) to Macromolecular Bioscience. The reviewer report and comments are included at the end of this e-mail.

I'm pleased to inform you that your manuscript has been accepted for publication without change.

The final version of your article can only be published once we have received a signed license agreement. You will soon receive an email invitation to register or log in to Wiley Author Services (<https://authorservices.wiley.com/index.html#login>). After logging into Wiley Author Services, please follow the on-screen instructions to confirm your corresponding author(s) and sign the appropriate license agreement.

We will copyedit the accepted version of your manuscript and if we require any further information at this stage, we will contact you. After copyediting, your proofs will be prepared and instructions for returning your proof corrections will be provided when the proofs are sent to you.

For research articles and reviews, Macromolecular Bioscience publishes Accepted Articles on Wiley Online Library. To facilitate rapid dissemination of your work, the accepted version of your article will be published online before copyediting, typesetting, and proofreading. Any subsequent changes to your article will be made through the editing and proofing process, and will be reflected in the version of record when it is published online in EarlyView.

Congratulations on your results, and thank you for choosing Macromolecular Bioscience for publishing your work. I hope you will consider us for the publication of your future manuscripts.

Yours sincerely,

Anne Pfisterer

P.S.: If you believe your images might be appropriate for use on the cover of Macromolecular Bioscience, and you would like your paper to be considered for the cover, please e-mail us your layout suggestions with a short description. For details on cover image preparation, please see the cover gallery on <http://www.mbs-journal.de>.

You can extend the reach and visibility of your research with a Video Abstract. These short videos turn your findings into an engaging and accessible overview that's perfect for sharing on websites and social media. Learn more at www.wileyauthors.com/eeo/videos.

P.P.S.: Please make sure to follow the publisher's guidelines for sharing the submitted, accepted, or final version of your article. For more information on the sharing policies of Macromolecular Bioscience and voluntary principles for article sharing, please review the Copyright Transfer Agreement, which is available at <https://authorservices.wiley.com/author-resources/Journal-Authors/licensing/licensing-info-faqs.html>. For general information about sharing principles, visit www.howcanishareit.com.

REVIEWER REPORT:

Please note that reviewers may not be numbered consecutively.

EVALUATION:

Reviewer's Responses to Questions

Please rate the importance compared to published work in this subject area.

Reviewer #1: Considerable - Top 30% in the subject area

Reviewer #3: Considerable - Top 30% in the subject area

Please rate the novelty compared to published work in this subject area.

Reviewer #1: Considerable - Top 30% in the subject area

Reviewer #3: Considerable - Top 30% in the subject area

Which aspects of scholarly presentation require improvement (if any)?

Reviewer #1: (No Response)

Reviewer #3: (No Response)

Do the methods, data and analysis (including statistical analysis where applicable) adequately test the hypothesis and support the conclusions?

Reviewer #1: (No Response)

Reviewer #3: (No Response)

Are the methods, data and analysis described in sufficient detail to be reproduced?

Reviewer #1: None

Reviewer #3: Yes

Where applicable, have the requested revisions been adequately addressed?

Reviewer #1: Yes

Reviewer #3: Yes

COMMENTS TO AUTHOR:

Reviewer #1: Authors have addressed previous comments satisfactorially. No further comments.

--

Dr. Anne Pfisterer, Editor
Macromolecular Bioscience
E-mail: mabi@wiley-vch.de
Tel: +49(0)6201-606-581

<http://www.mbs-journal.de>

Impact Factor (2021 Journal Citation Reports): 4.979

MRC Special Issue: 100 Years of Macromolecular Chemistry (Free Access)

<http://doi.wiley.com/10.1002/marc.v41.1>

MCP Special Issue: 100 Years of Macromolecular Chemistry (Free Access)

<http://doi.wiley.com/10.1002/macp.v221.1>

MBS Special Issue: 20 Years of Macromolecular Bioscience (Free Access)

<http://doi.wiley.com/10.1002/mabi.v20.1>

We invite you to celebrate 100 years of polymer science with us. Check out for details at: www.chemistryviews.org/polymer100

By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services, and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at <https://authorservices.wiley.com/statements/data-protection-policy.html>

Wiley-VCH GmbH - A company of John Wiley & Sons, Inc. - Location of the Company: Weinheim - Trade Register Mannheim, HRB 736569. Chairman of the Supervisory Board: John Kritzmacher. Managing Directors: Sabine Haag, Dr. Guido F. Herrmann.

Please be aware that if you ask to have your user record removed, we will retain your name in the records concerning manuscripts for which you were an author, reviewer, or editor.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/mbs-journal/login.asp?a=r>). Please contact the publication office if you have any questions.

Agustina Setiawati <nina.lifesci@gmail.com>

Wed, Jun 8, 2022 at 5:37 PM

To: 정광환 <kjung@sogang.ac.kr>

Prof Jung, this is the proof of my manuscript acceptance. I hope I still can catch up the defense

Thanks,
Nina

[Quoted text hidden]

FW: Production data for Macromolecular Bioscience mabi.202200106R1 - [EMID:3cb045adf468208e]

5 messages

kwshin@sogang.ac.kr <kwshin@sogang.ac.kr>
Reply-To: kwshin@sogang.ac.kr
To: Agustina Setiawati <nina.lifesci@gmail.com>
Cc: Ivan Brilian <ivan@sogang.ac.kr>

Tue, Jun 14, 2022 at 8:51 PM

Can you carefully find out whether your figures are fitting to the resolution?

-----Original Message-----

From: em.mbs-journal.0.7bfc84.df6aa911@editorialmanager.com <em.mbs-journal.0.7bfc84.df6aa911@editorialmanager.com> On Behalf Of Macromolecular Bioscience
Sent: Tuesday, June 14, 2022 4:42 PM
To: Kwanwoo Shin <kwshin@sogang.ac.kr>
Subject: Production data for Macromolecular Bioscience mabi.202200106R1 - [EMID:3cb045adf468208e]

Dear Prof. Shin,

Congratulations on the acceptance of your manuscript mabi.202200106R1, "Fabrication of a Tailored, Hybrid Extracellular Matrix Composite" to Macromolecular Bioscience!
We have reviewed your production data and would like to ask that you resubmit the following files:

Figures:

Unfortunately, the resolution of some of the figures as submitted may not be high enough for production. Please revise your figures 1 - 4, and ToC figure to a resolution of at least 300 dpi or greater and in the file format JPG, PNG, PDF, EPS, TIFF, PPTX, or DOCX. Any text in the figure should be clearly legible.

**** NOTE:** Please do not actually change the figures -- we require the accepted versions, and please send us ONLY these figures, thank you.

Please submit these files by 19 Jun 2022 to avoid delays in the processing of your manuscript.

Files may be uploaded using the following link <https://www.editorialmanager.com/mbs-journal/l.asp?i=123402&l=J6QMOV8W>

Select "Submit Task" from the Action menu to upload and submit your files. It is not possible to upload bundled files that exceed 40 MB. However, larger files can be uploaded separately as long as each individual file is less than 40 MB in size.

Please note: The production data must be the final version. You may be charged for any significant additions or changes made during correction of the page proofs. If you have any questions during the production data upload process, please do not hesitate to contact us.

Best regards,

Editorial Office
Macromolecular Bioscience

--
Macromolecular Bioscience
E-mail: mabi@wiley-vch.de
Tel: +49(0)6201-606-581

<http://www.mbs-journal.de>

Impact Factor (2021 Journal Citation Reports): 4.979

MRC Special Issue: 100 Years of Macromolecular Chemistry (Free Access)

<http://doi.wiley.com/10.1002/marc.v41.1>

MCP Special Issue: 100 Years of Macromolecular Chemistry (Free Access)

<http://doi.wiley.com/10.1002/macp.v221.1>

MBS Special Issue: 20 Years of Macromolecular Bioscience (Free Access)

We invite you to celebrate 100 years of polymer science with us. Check out for details at: www.chemistryviews.org/polymer100

By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services, and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at <https://authorservices.wiley.com/statements/data-protection-policy.html>

Wiley-VCH GmbH - A company of John Wiley & Sons, Inc. - Location of the Company: Weinheim - Trade Register Mannheim, HRB 736569. Chairman of the Supervisory Board: John Kritzmacher. Managing Directors: Sabine Haag, Dr. Guido F. Herrmann.

Please be aware that if you ask to have your user record removed, we will retain your name in the records concerning manuscripts for which you were an author, reviewer, or editor.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/mbs-journal/login.asp?a=r>). Please contact the publication office if you have any questions.

Agustina Setiawati <nina.lifesci@gmail.com>
To: Kwanwoo Shin <kwshin@sogang.ac.kr>
Cc: ivanbrilian96@gmail.com

Tue, Jun 14, 2022 at 11:44 PM

Dear Prof,

All of the Figures meet the resolution which is 300 dpi.

Nina

[Quoted text hidden]


kwshin@sogang.ac.kr <kwshin@sogang.ac.kr>
Reply-To: kwshin@sogang.ac.kr
To: Agustina Setiawati <nina.lifesci@gmail.com>
Cc: ivanbrilian96@gmail.com

Wed, Jun 15, 2022 at 1:38 PM

They asked because there might be issues, or TOC...Please reformat all the images and send me back to submit them. AND also the text in the figure, whether you can enlarge them to be more visible.

[Quoted text hidden]

2 attachments



 **Marked Tailored ECM-220524-Shin_NN.docx**
11191K

Agustina Setiawati <nina.lifesci@gmail.com>
To: Kwanwoo Shin <kwshin@sogang.ac.kr>
Cc: ivanbrilian96@gmail.com

Fri, Jun 17, 2022 at 4:44 PM

Dear Prof,

Please find the following figures and TOC, and the manuscript embedded with those figures.
<https://drive.google.com/file/d/1VqSHZRdZm5yYwXHpJiiNrvyI0G-K4RSM/view?usp=sharing>

Nina

[Quoted text hidden]

Agustina Setiawati <nina.lifesci@gmail.com>
To: Kwanwoo Shin <kwshin@sogang.ac.kr>
Cc: ivanbrilian96@gmail.com

Fri, Jun 17, 2022 at 6:09 PM

I am sorry Prof, there is a missing part in the previous email ππ
Please find the updated version attached

https://drive.google.com/file/d/1MN6e_zUETyZ33mDH7X7RQCW8eZV8KJix/view?usp=sharing

 **Macromol Biosci Shin et al Rev.rar**

Nina

[Quoted text hidden]